Board of Directors

Audit
Committee
Compensation
Committee
Nominating & Corporate
Governance Committee
AC
CC
NCGC

Charles J. Link Jr, MD, has served as chief executive officer since 2003, and chairman of the Board of Directors and chief scientific officer since founding the company in 1999. Following undergraduate study at the United States Air Force Academy, Dr Link received a BA degree from Stanford University and an MD degree from Stanford University School of Medicine in Stanford, California. He trained in internal medicine at the University of California, San Francisco, and continued fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland. Dr Link has authored more than 100 scientific articles and reviews.

Recent Stock Transactions by Charles J. Link, Jr, MD
Date Type Shares Traded Price Range
Jan 4, 2017 Disposition (Non Open Market) 3,169 11.04
Jan 3, 2017 Disposition (Non Open Market) 5,265 10.28
Apr 7, 2016 Automatic Sell 10,000 20.03
Mar 15, 2016 Automatic Sell 25,000 17.68 - 18.60
Feb 3, 2016 Automatic Sell 25,000 23.81 - 24.46
Jan 6, 2016 Automatic Sell 25,000 32.29 - 33.06
Jan 5, 2016 Sell 5,001 34.46 - 35.29
Jan 4, 2016 Acquisition (Non Open Market) 46,639 n/a
Dec 3, 2015 Automatic Sell 25,000 35.13 - 38.30
Nov 4, 2015 Automatic Sell 20,000 40.29 - 43.83
Oct 7, 2015 Automatic Sell 10,000 35.16
Oct 5, 2015 Automatic Sell 15,000 36.96 - 38.17
Sep 4, 2015 Automatic Sell 12,500 44.87
Sep 3, 2015 Automatic Sell 7,500 44.75 - 45.92
Aug 25, 2015 Disposition (Non Open Market) 15,000 n/a
Aug 25, 2015 Acquisition (Non Open Market) 15,000 n/a
Aug 5, 2015 Automatic Sell 20,000 51.92 - 52.68
Jul 6, 2015 Automatic Sell 20,000 43.72 - 45.55
Jun 17, 2015 Automatic Sell 20,000 44.29 - 45.19
Jun 3, 2015 Automatic Sell 20,000 44.28 - 44.90
May 5, 2015 Automatic Sell 20,000 46.38 - 47.81
Apr 6, 2015 Automatic Sell 20,000 53.01
Mar 4, 2015 Automatic Sell 20,000 45.66 - 48.31
Feb 5, 2015 Automatic Sell 12,500 32.56
Feb 4, 2015 Automatic Sell 7,500 32.15
Jan 7, 2015 Automatic Sell 15,000 37.77
Jan 6, 2015 Automatic Sell 5,000 38.51 - 42.25
Jan 2, 2015 Disposition (Non Open Market) 1,700 43.65
Jan 2, 2015 Acquisition (Non Open Market) 45,000 n/a
Dec 4, 2014 Automatic Sell 6,300 36.44 - 38.01
Dec 3, 2014 Automatic Sell 13,700 38.19
Nov 10, 2014 Automatic Sell 10,000 33.36
Nov 7, 2014 Automatic Sell 10,000 32.51
Oct 22, 2014 Automatic Sell 25,000 40.26
Oct 6, 2014 Automatic Sell 10,000 21.86
Oct 3, 2014 Automatic Sell 10,000 23.57
Sep 5, 2014 Automatic Sell 10,000 25.07
Sep 4, 2014 Automatic Sell 10,000 25.68 - 26.88
Aug 5, 2014 Automatic Sell 18,000 21.83
Jul 8, 2014 Automatic Sell 10,000 24.48
Jul 7, 2014 Automatic Sell 10,000 27.51
Jun 3, 2014 Automatic Sell 15,000 18.91
Jun 2, 2014 Automatic Sell 5,000 19.51
May 2, 2014 Automatic Sell 10,000 21.04
May 1, 2014 Automatic Sell 10,000 21.48
Apr 2, 2014 Automatic Sell 10,000 27.35 - 28.25
Apr 1, 2014 Automatic Sell 10,000 27.93 - 29.30
Mar 5, 2014 Automatic Sell 10,000 38.08
Mar 4, 2014 Automatic Sell 10,000 39.15 - 41.00
Feb 3, 2014 Automatic Sell 20,000 35.87

Thomas A. Raffin, MD, is lead director and has served as a member of the Board of Directors since 1999. Dr Raffin spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Dr Raffin received a BA from Stanford University and an MD from Stanford University School of Medicine and completed his medical residency at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital) in Boston, Massachusetts.

Recent Stock Transactions by Thomas A. Raffin, MD
Date Type Shares Traded Price Range
Apr 30, 2015 Acquisition (Non Open Market) 1,962 n/a
Apr 7, 2015 Automatic Sell 20,694 53.18 - 55.03
Apr 7, 2015 Option Execute 20,694 1.96 - 10.02
May 1, 2014 Acquisition (Non Open Market) 2,944 n/a
Jan 2, 2014 Acquisition (Non Open Market) 3,000 n/a
Nov 16, 2011 Acquisition (Non Open Market) 9,096 n/a
Nov 10, 2011 Statement of Ownership 0 n/a

Paul R. Edick was appointed to the Board of Directors in July 2011. Since July 2010, Mr Edick has been the chief executive officer of Durata Therapeutics, a start-up biopharmaceutical company. Previous positions held include chief executive officer of Ganic Pharmaceuticals, Chief Executive Officer of MedPointe Healthcare Inc., and president of MedPointe Healthcare Inc. Mr Edick holds a BA in Psychology from Hamilton College in Clinton, New York.

Recent Stock Transactions by Paul R. Edick
Date Type Shares Traded Price Range
Apr 30, 2015 Acquisition (Non Open Market) 1,962 n/a
May 1, 2014 Acquisition (Non Open Market) 2,944 n/a
Jan 2, 2014 Acquisition (Non Open Market) 3,000 n/a
Nov 10, 2011 Statement of Ownership 0 n/a

Paolo Pucci was appointed to the Board of Directors in November 2015. He is chief executive officer and a director of ArQule Inc., a clinical-stage biotechnology company that is researching and developing cancer therapeutics. Prior to ArQule, Paolo was senior vice president of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit at Bayer AG. He also served as an independent director of Dyax Corporation, until it was acquired by Shire Plc, and as an independent director of Algeta ASA, until it was acquired by Bayer AG. Paolo holds an MBA from the University of Chicago Booth School of Business and is a graduate of the Università Degli Studi di Napoli Federico II in Naples, Italy.

Recent Stock Transactions by Paolo Pucci
Date Type Shares Traded Price Range
Nov 12, 2015 Statement of Ownership 0 n/a

Joseph Saluri has served as a member of the Board of Directors since May 2010. Mr Saluri has served as vice president and general counsel for Stine Seed Company and its affiliates since July 1999. Previously, Mr Saluri was an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines and London. Mr Saluri received a BS/BA from Drake University and a JD from Drake University Law School in Des Moines, Iowa.

Recent Stock Transactions by Joseph Saluri
Date Type Shares Traded Price Range
Jul 13, 2015 Sell 5,000 50.42
Jul 13, 2015 Option Execute 5,000 3.07 - 13.30
Apr 30, 2015 Acquisition (Non Open Market) 1,962 n/a
May 1, 2014 Acquisition (Non Open Market) 2,944 n/a
Feb 7, 2014 Sell 4,761 38.80
Feb 7, 2014 Option Execute 4,761 3.07
Jan 2, 2014 Acquisition (Non Open Market) 3,000 n/a
Nov 16, 2011 Acquisition (Non Open Market) 8,142 n/a
Nov 10, 2011 Statement of Ownership 0 n/a

Ernest J. Talarico, III has served as a member of the Board of Directors since 1999. Mr Talarico has worked for Mesirow Financial Holdings, Inc., a diversified financial services firm headquartered in Chicago, Illinois, since 1998, where he has been a managing director since June 2008. Mr Talarico holds a bachelor's degree from the University of Iowa in Iowa City, Iowa, as well as licenses in equities, options, and managed futures.

Recent Stock Transactions by Ernest J. Talarico, III
Date Type Shares Traded Price Range
Jun 6, 2016 Buy 4,065 12.32
Apr 30, 2015 Acquisition (Non Open Market) 1,962 n/a
Mar 18, 2015 Sell 1,000 53.75
Mar 18, 2015 Option Execute 1,000 2.10
Mar 17, 2015 Sell 19,532 52.89
Mar 17, 2015 Option Execute 19,532 2.10
Jan 8, 2015 Disposition (Non Open Market) 1,438 n/a
Jan 8, 2015 Acquisition (Non Open Market) 1,438 n/a
May 1, 2014 Acquisition (Non Open Market) 2,944 n/a
Feb 7, 2014 Sell 25,000 37.06
Feb 7, 2014 Option Execute 25,000 1.95 - 2.10
Jan 2, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 28, 2012 Option Execute 2,380 0.53
Feb 15, 2012 Acquisition (Non Open Market) 2,714 n/a
Nov 16, 2011 Acquisition (Non Open Market) 9,096 n/a
Nov 10, 2011 Statement of Ownership 0 n/a

Nicholas Vahanian, MD, was appointed to the Board of Directors in November 2015. Dr Vahanian has served as president and chief medical officer of NewLink Genetics since 2009. He led the algenpantucel-L development program, including the IMPRESS trial. Dr Vahanian began his research career at the National Cancer Institute and continued on to the National Center for Human Genome Research Institute. Dr Vahanian holds a BS in biology from Virginia Commonwealth University in Richmond, Virginia, and an MBA from the University of Notre Dame in Notre Dame, Indiana. He attended St. Bartholomew's and Royal London Hospital Medical College where he earned his medical degree, and completed a fellowship in molecular oncology at the John Stoddard Cancer Research Institute in Urbandale, Iowa.

Recent Stock Transactions by Nicholas Vahanian, MD
Date Type Shares Traded Price Range
Jan 4, 2017 Disposition (Non Open Market) 2,085 11.04
Jan 3, 2017 Disposition (Non Open Market) 3,266 10.28
Jan 5, 2016 Sell 3,011 34.80 - 35.57
Jan 4, 2016 Acquisition (Non Open Market) 29,456 n/a
Sep 11, 2015 Automatic Sell 10,000 51.19
Sep 11, 2015 Option Execute 10,000 2.10
Aug 3, 2015 Automatic Sell 10,000 51.77
Aug 3, 2015 Option Execute 10,000 2.10
Jul 14, 2015 Automatic Sell 20,000 51.14
Jul 14, 2015 Option Execute 20,000 2.10
May 1, 2015 Automatic Sell 10,000 45.48 - 46.31
May 1, 2015 Option Execute 10,000 2.10
Apr 1, 2015 Automatic Sell 10,000 52.00 - 53.00
Apr 1, 2015 Option Execute 10,000 2.10
Mar 9, 2015 Automatic Sell 15,000 49.57
Mar 9, 2015 Option Execute 13,000 0.80 - 2.10
Mar 5, 2015 Automatic Sell 60,000 49.89
Mar 2, 2015 Automatic Sell 10,000 44.03 - 46.24
Jan 2, 2015 Disposition (Non Open Market) 1,161 43.65
Jan 2, 2015 Acquisition (Non Open Market) 25,000 n/a
Feb 4, 2014 Automatic Sell 25,000 36.78
Feb 4, 2014 Option Execute 15,000 2.10
Feb 3, 2014 Automatic Sell 20,000 35.87
Jan 14, 2014 Automatic Sell 35,000 26.58
Jan 14, 2014 Option Execute 18,664 2.10
Jan 13, 2014 Automatic Sell 10,000 26.00
Jan 3, 2014 Disposition (Non Open Market) 2,838 22.19
Jan 3, 2014 Automatic Sell 27,162 22.19
Jan 3, 2014 Option Execute 30,000 0.80 - 2.10
Jan 2, 2014 Acquisition (Non Open Market) 24,500 n/a
Dec 2, 2013 Automatic Sell 30,000 22.19
Nov 29, 2013 Automatic Sell 7,500 22.07
Nov 27, 2013 Automatic Sell 4,500 22.16
Nov 19, 2013 Automatic Sell 3,800 18.04
Nov 18, 2013 Automatic Sell 2,200 18.06
Nov 5, 2013 Automatic Sell 4,000 18.03
Nov 1, 2013 Automatic Sell 8,000 17.28
Jun 10, 2013 Automatic Sell 20,000 19.90
Jul 26, 2012 Option Execute 30,395 2.10 - 4.20
Nov 16, 2011 Acquisition (Non Open Market) 99,226 n/a
Nov 10, 2011 Statement of Ownership 0 n/a
Nov 10, 2011 Statement of Ownership 0 n/a

Lota has served as a member of the Board of Directors since November 2012. Lota served as senior vice president and chief financial officer of MedImmune, Inc. from April 2004 to July 2007, before which she served as its controller and principal accounting officer. Lota also served as an auditor at Ernst & Young, LLP and is a certified public accountant. She received a BBA in accounting from Texas Tech University in Lubbock, Texas.

Recent Stock Transactions by Lota S. Zoth
Date Type Shares Traded Price Range
Apr 30, 2015 Acquisition (Non Open Market) 1,962 n/a
May 1, 2014 Acquisition (Non Open Market) 2,944 n/a
Jan 2, 2014 Acquisition (Non Open Market) 3,000 n/a

Stock transaction information provided by EDGAR Online. NewLink Genetics Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.